Corporate Banner
Satellite Banner
Proteomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Evotec and Dow AgroSciences Collaborate on Cellular Target Profiling

Published: Tuesday, July 09, 2013
Last Updated: Tuesday, July 09, 2013
Bookmark and Share
Collaboration has objective of leveraging Evotec’s advanced chemical proteomics services to support compounds in development at Dow AgroSciences.

To this end, Evotec will perform quantitative chemical proteomics services (Cellular Target Profiling) to de-convolute phenotypic screening results obtained by Dow.

Dr Mario Polywka, Chief Operating Officer of Evotec, commented: “We look forward to working with Dow AgroSciences on this project. This collaboration highlights the broad applicability of Evotec‘s industry leading chemical proteomics platform to determine cellular target affinities and mechanisms of action on a proteome wide level and in a native context.”

Dr William Kleschick, Discovery Global Leader of Dow AgroSciences, added: “Dow AgroSciences is pleased to announce this new partnership with Evotec, an innovative leader in advanced chemical proteomics. This collaboration enhances Discovery’s technology tool-box to accelerate our efforts to deliver novel solutions to our customers around the world.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Evotec Receives First Milestone in Roche Biomarker Collaboration
Evotec AG announce the successful achievement of a milestone in its biomarker alliance with Roche.
Thursday, April 24, 2014
Evotec Earns Milestone in Oncology Programme as Part of its Research Alliance with Boehringer Ingelheim
The milestone was achieved for the selection of a candidate compound for pre-development studies in an oncology programme.
Thursday, June 17, 2010
Evotec Enters into Integrated Drug Discovery Alliance with Genentech
Evotec to apply its integrated drug discovery platform in combination with its disease biology expertise against targets nominated by Genentech.
Tuesday, May 11, 2010
Evotec Signs High Throughput Screening Agreement with Active Biotech
The Collaboration is aimed at identifying small molecule modulators of priority biological targets involved in immune disorders and cancer.
Friday, March 12, 2010
Evotec Extends Medicinal Chemistry Collaboration with Ono Pharmaceutical
Ono to access Evotec’s ion channel drug discovery platform and expertise and Evotec to receive research funding and milestone payments.
Monday, October 19, 2009
Evotec Announces Research Agreement with Biogen Idec
Evotec will use its expertise and capabilities in compound screening to identify hit compounds.
Thursday, September 10, 2009
EVOTEC Announces RESEARCH Agreement on Fragment-Based Drug Discovery with Cubist
Cubist will use Evotec’s fragment screening technology to complement discovery research efforts in two of its antibacterials programs.
Wednesday, July 15, 2009
Evotec to Re-engineer Drug Discovery and Development Operations
Evotec to concentrate all proprietary core research programs at its European operations.
Friday, May 08, 2009
Evotec Presents its Fragment Screening Technology at Two Key Conferences
Presentations will be given at Screening, MedChem and ADMET Europe and at the Molecular Medicine Tri-Conference.
Thursday, February 19, 2009
Spermatech Selects Evotec as Partner for High-Throughput Screening and Lead Discovery
Evotec is chosen to apply its expertise in assay development and NMR screening to identify inhibitors of the sperm specific target protein.
Thursday, March 20, 2008
Scientific News
ASMS 2016: Targeting Mass Spectrometry Tools for the Masses
The expanding application range of MS in life sciences, food, energy, and health sciences research was highlighted at this year's ASMS meeting in San Antonio, Texas.
“Amazing Protein Diversity” Discovered in Maize
The genome of the corn plant – or maize, as it’s called almost everywhere except the US – “is a lot more exciting” than scientists have previously believed. So says the lead scientist in a new effort to analyze and annotate the depth of the plant’s genetic resources.
Proteins in Blood of Heart Disease Patients May Predict Adverse Events
Nine-protein test shown superior to conventional assessments of risk.
Self-Assembling Protein Shell for Drug Delivery
Made-to-order nano-cages open possibilities of shipping cargo into living cells or fashioning small chemical reactors.
Molecular Map Provides Clues To Zinc-Related Diseases
Mapping the molecular structure where medicine goes to work is a crucial step toward drug discovery against deadly diseases.
Nanoprobe Enables Measurement of Protein Dynamics in Living Cells
Mass. General and Harvard researchers use device to measure how anesthetic affects levels of Alzheimer's-associated proteins.
Diagnosing Systemic Infections Quickly, Reliably
Team develop rapid and specific diagnostic assay that could help physicians decide within an hour whether a patient has a systemic infection and should be hospitalized for aggressive intervention therapy.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
A New Tool Brings Personalized Medicine Closer
Scientists from EPFL and ETHZ have developed a powerful tool for exploring and determining the inherent biological differences between individuals, which overcomes a major hurdle for personalized medicine.
Blood Test That Detects Early Alzheimer’s Disease
A research team, led by Dr. Robert Nagele from Rowan University School of Osteopathic Medicine and Durin Technologies, Inc., has announced the development of a blood test that leverages the body’s immune response system to detect an early stage of Alzheimer’s disease – referred to as the mild cognitive impairment (MCI) stage – with unparalleled accuracy.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!